Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: A retrospective study of two independent tumour tissue collections

The Lancet Oncology

Volumn 12, Issue 3, 2011, Pages 273-285

  Marchini, Sergio ^a   Cavalieri, Duccio ^c   Fruscio, Robert ^b,g   Calura, Enrica ^d   Garavaglia, Daniela ^a   Nerini, Ilaria Fuso ^a   Mangioni, Costantino ^b,g   Cattoretti, Giorgio ^b   Clivio, Luca ^a   Beltrame, Luca ^c   Katsaros, Dionyssios ^e,g   Scarampi, Luca ^e   Menato, Guido ^e   Perego, Patrizia ^b   Chiorino, Giovanna ^f   Buda, Alessandro ^b   Romualdi, Chiara ^d   D'Incalci, Maurizio ^a,g  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b SAN GERARDO HOSPITAL   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

^f Fondo Edo Tempia   (Italy)

^g MaNGO Group   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 143; MICRORNA 145; MICRORNA 199A 3P; MICRORNA 199A 5P; MICRORNA 200B; MICRORNA 200C; MICRORNA 20A; MICRORNA 214; MICRORNA 30A; MICRORNA 30D; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; EPITHELIAL OVARIAN CANCER; FEMALE; FOLLOW UP; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MICRORNAS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 79952041791     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(11)70012-2     Document Type: Article

References (34)

1. Cannistra SA Cancer of the ovary. N Engl J Med 2004, 351:2519-2529.
2. Marabese M, Marchini S, Marrazzo E, et al. Expression levels of p53 and p73 isoforms in stage I and stage III ovarian cancer. Eur J Cancer 2008, 44:131-141.
3. Marchini S, Marabese M, Marrazzo E, et al. DeltaNp63 expression is associated with poor survival in ovarian cancer. Ann Oncol 2008, 19:501-507.
4. Marchini S, Mariani P, Chiorino G, et al. Analysis of gene expression in early-stage ovarian cancer. Clin Cancer Res 2008, 14:7850-7860.
5. Bartel DP MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
6. Merritt WM, Lin YG, Han LY, et al. Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med 2008, 359:2641-2650.
7. Trimbos JB, Parmar M, Vergote I, et al. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 2003, 95:105-112.
8. Bolstad BM, Irizarry RA, Astrand M, Speed TP A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003, 19:185-193.
9. Storey JD, Tibshirani R Statistical significance for genomewide studies. Proc Natl Acad Sci USA 2003, 100:9440-9445.
10. Saeed AI, Sharov V, White J, et al. TM4: a free, open-source system for microarray data management and analysis. Biotechniques 2003, 34:374-378.
11. Lewis BP, Burge CB, Bartel DP Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120:15-20.
12. Friedman RC, Farh KK, Burge CB, Bartel DP Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009, 19:92-105.
13. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
14. Williams BA, Mandrekar JN, Mandrekar SJ, Cha SS, Furth AF Finding optimal cutpoints for continuous covariates with binary and time-to-event outcomes 2006, Mayo Clinic, Rochester, MN.
15. Hanley JA, McNeil BJ A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983, 148:839-843.
16. Lim LP, Lau NC, Garrett-Engele P, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005, 433:769-773.
17. Ie M Shih, Kurman RJ Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004, 164:1511-1518.
18. Cummins JM, Velculescu VE Implications of micro-RNA profiling for cancer diagnosis. Oncogene 2006, 25:6220-6227.
19. Dalmay T, Edwards DR MicroRNAs and the hallmarks of cancer. Oncogene 2006, 25:6170-6175.
20. Tricoli JV, Jacobson JW MicroRNA: potential for cancer detection, diagnosis, and prognosis. Cancer Res 2007, 67:4553-4555.
21. van Jaarsveld MT, Helleman J, Berns EM, Wiemer EA MicroRNAs in ovarian cancer biology and therapy resistance. Int J Biochem Cell Biol 2011, 42:1282-1290.
22. Iorio MV, Visone R, Di Leva G, et al. MicroRNA signatures in human ovarian cancer. Cancer Res 2007, 67:8699-8707.
23. Zhang L, Huang J, Yang N, et al. microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci USA 2006, 103:9136-9141.
24. Eitan R, Kushnir M, Lithwick-Yanai G, et al. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients. Gynecol Oncol 2009, 114:253-259.
25. Korpal M, Kang Y The emerging role of miR-200 family of microRNAs in epithelial-mesenchymal transition and cancer metastasis. RNA Biol 2008, 5:115-119.
26. Nam EJ, Yoon H, Kim SW, et al. MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 2008, 14:2690-2695.
27. Hu X, Macdonald DM, Huettner PC, et al. A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecol Oncol 2009, 114:457-464.
28. Alexiou P, Maragkakis M, Papadopoulos GL, Reczko M, Hatzigeorgiou AG Lost in translation: an assessment and perspective for computational microRNA target identification. Bioinformatics 2009, 25:3049-3055.
29. Liu H, Brannon AR, Reddy AR, et al. Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell Renal Cell Carcinoma. BMC Syst Biol 2010, 4:51.
30. Burger RA, Brady MF, Bookman MA, et al. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cavity (PPC), or fallopian tube cancer (FTC): a Gynecologic Oncology Group study. Proc Am Soc Clin Oncol 2010, 28. abstr 5015.
31. Cochrane DR, Spoelstra NS, Howe EN, Nordeen SK, Richer JK MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther 2009, 8:1055.
32. Ferrandina G, Zannoni GF, Martinelli E, et al. Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin Cancer Res 2006, 12:2774-2779.
33. Leskela S, Leandro-Garcia LJ, Mendiola M, et al. miR-200 family controls {beta}-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients. Endocr Relat Cancer 2010, 18:85-95.
34. Taylor DD, Gercel-Taylor C MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 2008, 110:13-21.